ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor
Conditions
Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Trial Timeline
Oct 26, 2020 → Feb 28, 2027
NCT ID
NCT04516447About ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04516447. Target conditions include Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04516447 | Phase 1 | Recruiting |
Competing Products
20 competing products in Solid Tumor